Patents by Inventor Mikkel Ole Skjodt
Mikkel Ole Skjodt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945848Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: August 9, 2022Date of Patent: April 2, 2024Assignee: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20230295252Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: August 9, 2022Publication date: September 21, 2023Applicant: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 11453709Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: July 16, 2020Date of Patent: September 27, 2022Assignee: OMEROS CORPORATIONInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 11203622Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to antibodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: GrantFiled: May 31, 2017Date of Patent: December 21, 2021Assignee: Omeros CorporationInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20210009643Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: July 16, 2020Publication date: January 14, 2021Applicant: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 10752661Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: October 11, 2017Date of Patent: August 25, 2020Assignee: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 10294286Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: January 6, 2017Date of Patent: May 21, 2019Assignee: OMEROS CORPORATIONInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20180273593Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: October 11, 2017Publication date: September 27, 2018Applicant: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20170334961Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to antibodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: May 31, 2017Publication date: November 23, 2017Applicants: Rigshospitalet, Københavns Universitet, Syddansk UniversitetInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Patent number: 9815876Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: March 4, 2011Date of Patent: November 14, 2017Assignee: Omeros CorporationInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20170166616Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: January 6, 2017Publication date: June 15, 2017Applicants: Rigshospitalet, Kobenhavns Universitet, Syddansk UniversitetInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 9573984Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: December 30, 2014Date of Patent: February 21, 2017Assignees: RIGSHOSPITALET, KOBENHAVNS UNIVERSITET, SYDDANSK UNIVERSITETInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20150210743Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: December 30, 2014Publication date: July 30, 2015Inventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 8852869Abstract: The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier.Type: GrantFiled: September 5, 2008Date of Patent: October 7, 2014Assignee: Immunobond ApSInventors: Yaseelan Palarasah, Mikkel Ole Skjødt, Lars Vitved, Claus Koch
-
Publication number: 20130217616Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: March 4, 2011Publication date: August 22, 2013Inventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20120282285Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: July 16, 2010Publication date: November 8, 2012Applicants: RIGSHOSPITALET, SYDDANSK UNIVERSITET, KØBENHAVNS UNIVERSITETInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20100196927Abstract: The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier.Type: ApplicationFiled: September 5, 2008Publication date: August 5, 2010Applicant: Immunobond ApSInventors: Yaseelan Palarasah, Mikkel Ole Skjodt, Lars Vitved, Claus Koch